|
1
|
Gupta A and Dwivedi T: A simplified
overview of World Health Organization classification update of
central nervous system tumors 2016. J Neurosci Rural Pract.
8:629–641. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
PDQ Pediatric Treatment Editorial Board:
Childhood ependymoma treatment (PDQ®): Health
professional version. 2002.
|
|
3
|
Zamecnik J, Snuderl M, Eckschlager T,
Chanova M, Hladikova M, Tichy M and Kodet R: Pediatric intracranial
ependymomas: Prognostic relevance of histological,
immunohistochemical, and flow cytometric factors. Mod Pathol.
16:980–991. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hübner JM, Kool M, Pfister SM and Pajtler
KW: Epidemiology, molecular classification and WHO grading of
ependymoma. J Neurosurg Sci. 62:46–50. 2018.PubMed/NCBI
|
|
5
|
Pajtler KW, Witt H, Sill M, Jones DT,
Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C,
Johann P, et al: Molecular classification of ependymal tumors
across all CNS compartments, histopathological grades, and age
groups. Cancer Cell. 27:728–743. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pajtler KW, Mack SC, Ramaswamy V, Smith
CA, Witt H, Smith A, Hansford JR, von Hoff K, Wright KD, Hwang E,
et al: The current consensus on the clinical management of
intracranial ependymoma and its distinct molecular variants. Acta
Neuropathol. 133:5–12. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tihan T, Zhou T, Holmes E, Burger PC,
Ozuysal S and Rushing EJ: The prognostic value of histological
grading of posterior fossa ependymomas in children: A Children's
Oncology Group study and a review of prognostic factors. Mod
Pathol. 21:165–177. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bentwich I, Avniel A, Karov Y, Aharonov R,
Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, et al:
Identification of hundreds of conserved and nonconserved human
microRNAs. Nat Genet. 37:766–770. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vannini I, Fanini F and Fabbri M: Emerging
roles of microRNAs in cancer. Curr Opin Genet Dev. 48:128–133.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zakrzewska M, Fendler W, Zakrzewski K,
Sikorska B, Grajkowska W, Dembowska-Bagińska B, Filipek I,
Stefańczyk Ł and Liberski PP: Altered MicroRNA expression is
associated with tumor grade, molecular background and outcome in
childhood infratentorial ependymoma. PLoS One. 11:e01584642016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Costa FF, Bischof JM, Vanin EF, Lulla RR,
Wang M, Sredni ST, Rajaram V, Mde Bonaldo F, Wang D, Goldman S, et
al: Identification of microRNAs as potential prognostic markers in
ependymoma. PLoS One. 6:e251142011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee
DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al:
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic
Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wiggins JF, Ruffino L, Kelnar K, Omotola
M, Patrawala L, Brown D and Bader AG: Development of a lung cancer
therapeutic based on the tumor suppressor microRNA-34. Cancer Res.
70:5923–5930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Misso G, Di Martino MT, De Rosa G, Farooqi
AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P,
Tassone P and Caraglia M: Mir-34: A new weapon against cancer? Mol
Ther Nucleic Acids. 3:e1942014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boyerinas B, Park SM, Hau A, Murmann AE
and Peter ME: The role of let-7 in cell differentiation and cancer.
Endocr Relat Cancer. 17:F19–F36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kolenda T, Przybyła W, Teresiak A,
Mackiewicz A and Lamperska KM: The mystery of let-7d-a small RNA
with great power. Contemp Oncol (Pozn). 18:293–301. 2014.PubMed/NCBI
|
|
19
|
Leeper H, Felicella MM and Walbert T:
Recent advances in the classification and treatment of ependymomas.
Curr Treat Options Oncol. 18:552017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang CH, Wang Y, Sims M, Cai C, He P,
Häcker H, Yue J, Cheng J, Boop FA and Pfeffer LM: MicroRNA203a
suppresses glioma tumorigenesis through an ATM-dependent interferon
response pathway. Oncotarget. 8:112980–112991. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liao H, Bai Y, Qiu S, Zheng L, Huang L,
Liu T, Wang X, Liu Y, Xu N, Yan X and Guo H: MiR-203 downregulation
is responsible for chemoresistance in human glioblastoma by
promoting epithelial-mesenchymal transition via SNAI2. Oncotarget.
6:8914–8928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang L, Sun H, Wang X, Hou N, Zhao L, Tong
D, He K, Yang Y, Song T, Yang J and Huang C: EGR1 mediates miR-203a
suppress the hepatocellular carcinoma cells progression by
targeting HOXD3 through EGFR signaling pathway. Oncotarget.
7:45302–45316. 2016.PubMed/NCBI
|
|
23
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bovell LC, Shanmugam C, Putcha BD,
Katkoori VR, Zhang B, Bae S, Singh KP, Grizzle WE and Manne U: The
prognostic value of microRNAs varies with patient race/ethnicity
and stage of colorectal cancer. Clin Cancer Res. 19:3955–3965.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Greither T, Grochola LF, Udelnow A,
Lautenschläger C, Würl P and Taubert H: Elevated expression of
microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated
with poorer survival. Int J Cancer. 126:73–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu G, Lai P, Liu M, Xu L, Guo Z, Liu H, Li
W, Wang G, Yao X, Zheng J and Xu Y: miR-203a regulates
proliferation, migration, and apoptosis by targeting glycogen
synthase kinase-3β in human renal cell carcinoma. Tumour Biol.
35:11443–11453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Birks DK, Barton VN, Donson AM, Handler
MH, Vibhakar R and Foreman NK: Survey of MicroRNA expression in
pediatric brain tumors. Pediatr Blood Cancer. 56:211–216. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Margolin-Miller Y, Yanichkin N, Shichrur
K, Toledano H, Ohali A, Tzaridis T, Michowitz S, Fichman-Horn S,
Feinmesser M, Pfister SM, et al: Prognostic relevance of miR-124-3p
and its target TP53INP1 in pediatric ependymoma. Genes Chromosomes
Cancer. 56:639–650. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang Y, Yang W, Zhu Y and Yuan Y:
Prognostic role of microRNA-203 in various carcinomas: Evidence
from a meta-analysis involving 13 studies. Springerplus.
5:15382016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Siebolts U, Varnholt H, Drebber U, Dienes
HP, Wickenhauser C and Odenthal M: Tissues from routine pathology
archives are suitable for microRNA analyses by quantitative PCR. J
Clin Pathol. 62:84–88. 2009. View Article : Google Scholar : PubMed/NCBI
|
